Citations

Clear

590 citation(s) found for "Ho, Ben".

Identification of Concealed and Manifest Long QT Syndrome Using a Novel T Wave Analysis Program
Sugrue, Alan , Křemen, Václav , Bos, J. Martijn , Qiang, Bo , Rohatgi, Ram K., Sapir, Yehu , Brady, Peter A. , Asirvatham, Samuel J. , Friedman, Paul A. , Ackerman, Michael J. , Noseworthy, Peter A. , Attia, Zachi I. , Asirvatham, Samuel J , Kremen, Vaclav , Bos, Johan M

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 13, 2016 | Volume: 9 | Issue: 7 | Pages: No page available

10.1161/circep.115.003830 | PMID 27406603 Get It

Background— Congenital long QT syndrome (LQTS) is characterized by QT prolongation. However, the QT interval itself is insufficient for diagnosis, unless the corrected QT interval is repeatedly ≥500 ms without an acquired explanation. Further, the majority of LQTS patients have a corrected QT interval below this threshold, and a significant minority has normal resting corrected QT interval values. Here, we aimed to develop and validate a novel, quantitative T wave morphological analysis program to differentiate LQTS patients from healthy controls. Methods and Results— We analyzed a genotyped cohort of 420 patients (22±16 years, 43% male) with either LQT1 (61%) or LQT2 (39%). ECG analysis was conducted using a novel, proprietary T wave analysis program that quantitates subtle changes in T wave morphology. The top 3 discriminating features in each ECG lead were determined and the lead with the best discrimination selected. Classification was performed using a linear discriminant classifier and validated on an untouched cohort. The top 3 features were Tpeak–Tend interval, T wave left slope, and T wave center of gravity x axis (last 25% of the T wave). Lead V6 had the best discrimination. It could distinguish 86.8% of LQTS patients from healthy controls. Moreover, it distinguished 83.33% of patients with concealed LQTS from controls, despite having essentially identical resting corrected QT interval values. Conclusions— T wave quantitative analysis on the 12-lead surface ECG provides an effective, novel tool to distinguish patients with either LQT1/LQT2 from healthy matched controls. It can provide guidance while mutation-specific genetic testing is in motion for family members.
Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
Binder, Moritz , Zhang, Ben , Kohli, Rhea, Kohli, Tanvi, Kohli, Manish , Zhang, Ben Y., Hillman, David W. , Lee, Adam , Binder, Moritz , Kohli, Manish

Mayo Clinic

International Journal of Molecular Sciences | July 11, 2016 | Volume: 17 | Issue: 7 | Pages: 1097

10.3390/ijms17071097 | PMID 27409606 Get It

Treatment with abiraterone acetate and prednisone (AA/P) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. We evaluated the genetic variation in CYP17A1 as predictive of response to AA/P. A prospective collection of germline DNA prior to AA/P initiation and follow-up of a mCRPC cohort was performed. Five common single-nucleotide polymorphisms (SNPs) in CYP17A1 identified using a haplotype-based tagging algorithm were genotyped. Clinical outcomes included biochemical response and time to biochemical progression on AA/P. Logistic regression was used to assess the association between tag SNPs and biochemical response. Proportional hazards regression was used to assess the association between tag SNPs and time to biochemical progression. Odds or hazard ratio per minor allele were estimated and p-values below 0.05 were considered statistically significant. Germline DNA was successfully genotyped for four tag SNPs in 87 patients. The median age was 73 years (54–90); the median prostate-specific antigen was 66 ng/dL (0.1–99.9). A single SNP, rs2486758, was associated with lower odds of experiencing a biochemical response (Odds ratio 0.22, 95% confidence interval 0.07–0.63, p = 0.005) and a shorter time to biochemical progression (Hazard ratio 2.23, 95% confidence interval 1.39–3.56, p < 0.001). This tag SNP located in the promoter region of CYP17A1 will need further validation as a predictive biomarker for AA/P therapy.
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1
Rodriguez, Vilmarie , Kairalla, John A. , Salzer, Wanda L. , Raetz, Elizabeth A. , Loh, Mignon L. , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Asselin, Barbara L. , Carroll, William L. , Dreyer, ZoAnn E., Wood, Brent L. , Burke, Michael J , Devidas, Meenakshi , Winick, Naomi Joan , Hunger, Stephen P. , Dreyer, ZoAnn E. , Loh, Mignon L

Mayo Clinic

Journal of Pediatric Hematology/Oncology | June 14, 2016 | Volume: 38 | Issue: 6 | Pages: 409-417

10.1097/mph.0000000000000589 | PMID 27299599 Get It

AALL08P1 was designed to determine whether biweekly intensified pegaspargase (I-PEG) was feasible and safe in pediatric patients with newly diagnosed high-risk B-precursor lymphoblastic leukemia when given with Children’s Oncology Group hemiaugmented BFM therapy. High-risk average (HR-Avg) patients received standard pegaspargase dosing (6 doses), whereas high-risk high (HR-High) patients received I-PEG biweekly from the start of Consolidation until day 1 of Maintenance. Feasibility and safety were defined in advance as ≥65% of patients tolerating at least 8 doses of I-PEG and 90% requiring ≤49 weeks from day 1 of Consolidation to the initiation of Maintenance. Targeted toxicities included allergic reactions, anaphylaxis, pancreatitis, thrombosis, bleeding, central nervous system events, and sepsis. AALL08P1 enrolled 104 patients; 54 were classified as HR-Avg and 30 as HR-High after completion of induction therapy. Only 53% (16/30) of the HR-High patients received ≥8 total doses of I-PEG and 50% (15/30) took ≤49 weeks from start of Consolidation to the initiation of Maintenance. I-PEG did not significantly increase grade 2 to 5 targeted toxicities. I-PEG was not feasible or safe as defined in AALL08P1. Complete assessment of this regimen was limited due to removal of patients from I-PEG regimen and early closure of the study.
10 Electrocardiographic predictors of torsadogenic risk during dofetilide or sotalol initiation: utility of a novel T wave analysis programme
Sugrue, Alan , Křemen, Václav , Qiang, Bo , Friedman, Paul A. , Ackerman, Michael J. , Sheldon, Seth H. , DeSimone, Christopher V. , Asirvatham, Samuel J. , Noseworthy, Peter A. , Kremen, Vaclav

Mayo Clinic

Moderated Poster Abstracts 1 | June 8, 2016 | Volume: No volume available | Issue: No issue available | Pages: A5.2-A5

10.1136/heartjnl-2015-308621.10 Get It

The functional organization of human epileptic hippocampus
Klimeš, Petr , Duque, Juliano J., Brinkmann, Benjamin H. , Stead, Matt, Louis, Erik K. St. , Halámek, Josef , Jurák, Pavel , Brinkmann, Ben, Van Gompel, Jamie, St Louis, Erik K, Gompel, Jamie J. Van , Worrell, Gregory A. , St Louis, E K , Brinkmann, Benjamin H , Klimes, Petr

Mayo Clinic

Journal of Neurophysiology | March 31, 2016 | Volume: 115 | Issue: 6 | Pages: 3140-3145

10.1152/jn.00089.2016 | PMID 27030735 Get It

The function and connectivity of human brain is disrupted in epilepsy. We previously reported that the region of epileptic brain generating focal seizures, i.e., the seizure onset zone (SOZ), is functionally isolated from surrounding brain regions in focal neocortical epilepsy. The modulatory effect of behavioral state on the spatial and spectral scales over which the reduced functional connectivity occurs, however, is unclear. Here we use simultaneous sleep staging from scalp EEG with intracranial EEG recordings from medial temporal lobe to investigate how behavioral state modulates the spatial and spectral scales of local field potential synchrony in focal epileptic hippocampus. The local field spectral power and linear correlation between adjacent electrodes provide measures of neuronal population synchrony at different spatial scales, ∼1 and 10 mm, respectively. Our results show increased connectivity inside the SOZ and low connectivity between electrodes in SOZ and outside the SOZ. During slow-wave sleep, we observed decreased connectivity for ripple and fast ripple frequency bands within the SOZ at the 10 mm spatial scale, while the local synchrony remained high at the 1 mm spatial scale. Further study of these phenomena may prove useful for SOZ localization and help understand seizure generation, and the functional deficits seen in epileptic eloquent cortex.
Effect of Off-Axis Fluoroscopy Imaging on Two-Dimensional Kinematics in the Lumbar Spine: A Dynamic In Vitro Validation Study
Zhao, Kristin D. , Ben‐Abraham, Ephraim I., Magnuson, Dixon J., Camp, Jon J. , Berglund, Lawrence J., An, Kai‐Nan , Brønfort, Gert , Gay, Ralph E. , Trentadue, Taylor P

Mayo Clinic

Journal of Biomechanical Engineering | March 14, 2016 | Volume: 138 | Issue: 5 | Pages: No page available

10.1115/1.4032995 | PMID 26974192 Get It

Spine intersegmental motion parameters and the resultant regional patterns may be useful for biomechanical classification of low back pain (LBP) as well as assessing the appropriate intervention strategy. Because of its availability and reasonable cost, two-dimensional (2D) fluoroscopy has great potential as a diagnostic and evaluative tool. However, the technique of quantifying intervertebral motion in the lumbar spine must be validated, and the sensitivity assessed. The purpose of this investigation was to (1) compare synchronous fluoroscopic and optoelectronic measures of intervertebral rotations during dynamic flexion–extension movements in vitro and (2) assess the effect of C-arm rotation to simulate off-axis patient alignment on intervertebral kinematics measures. Six cadaveric lumbar–sacrum specimens were dissected, and active marker optoelectronic sensors were rigidly attached to the bodies of L2–S1. Fluoroscopic sequences and optoelectronic kinematic data (0.15-mm linear, 0.17–0.20 deg rotational, accuracy) were obtained simultaneously. After images were obtained in a true sagittal plane, the image receptor was rotated in 5 deg increments (posterior oblique angulations) from 5 deg to 15 deg. Quantitative motion analysis (qma) software was used to determine the intersegmental rotations from the fluoroscopic images. The mean absolute rotation differences between optoelectronic values and dynamic fluoroscopic values were less than 0.5 deg for all the motion segments at each off-axis fluoroscopic rotation and were not significantly different (P > 0.05) for any of the off-axis rotations of the fluoroscope. Small misalignments of the lumbar spine relative to the fluoroscope did not introduce measurement variation in relative segmental rotations greater than that observed when the spine and fluoroscope were perpendicular to each other, suggesting that fluoroscopic measures of relative segmental rotation during flexion–extension are likely robust, even when patient alignment is not perfect.
Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy
Cohen, Itay , Kayode, Olumide, Hockla, Alexandra , Sankaran, Banumathi , Radisky, Evette S. , Papo, Niv , Radisky, Derek C. , Radisky, Evette S

Mayo Clinic

Biochemical Journal | March 8, 2016 | Volume: 473 | Issue: 10 | Pages: 1329-1341

10.1042/bj20151410 | PMID 26957636 Get It

Engineered protein therapeutics offer advantages, including strong target affinity, selectivity and low toxicity, but like natural proteins can be susceptible to proteolytic degradation, thereby limiting their effectiveness. A compelling therapeutic target is mesotrypsin, a protease up-regulated with tumour progression, associated with poor prognosis, and implicated in tumour growth and progression of many cancers. However, with its unique capability for cleavage and inactivation of proteinaceous inhibitors, mesotrypsin presents a formidable challenge to the development of biological inhibitors. We used a powerful yeast display platform for directed evolution, employing a novel multi-modal library screening strategy, to engineer the human amyloid precursor protein Kunitz protease inhibitor domain (APPI) simultaneously for increased proteolytic stability, stronger binding affinity and improved selectivity for mesotrypsin inhibition. We identified a triple mutant APPIM17G/I18F/F34V, with a mesotrypsin inhibition constant (Ki) of 89 pM, as the strongest mesotrypsin inhibitor yet reported; this variant displays 1459-fold improved affinity, up to 350 000-fold greater specificity and 83-fold improved proteolytic stability compared with wild-type APPI. We demonstrated that APPIM17G/I18F/F34V acts as a functional inhibitor in cell-based models of mesotrypsin-dependent prostate cancer cellular invasiveness. Additionally, by solving the crystal structure of the APPIM17G/I18F/F34V–mesotrypsin complex, we obtained new insights into the structural and mechanistic basis for improved binding and proteolytic resistance. Our study identifies a promising mesotrypsin inhibitor as a starting point for development of anticancer protein therapeutics and establishes proof-of-principle for a novel library screening approach that will be widely applicable for simultaneously evolving proteolytic stability in tandem with desired functionality for diverse protein scaffolds.
Novel Bloodless Potassium Determination Using a Signal‐Processed Single‐Lead ECG
Sapir, Yehu , Dugan, Jennifer , Ackerman, Michael J. , Asirvatham, Samuel J. , Striemer, Bryan L., Bukartyk, Jan , Bennet, Kevin E. , Ladewig, Dorothy J., Gilles, Emily J., Sadot, Dan , Geva, Amir B. , Friedman, Paul A. , Dillon, John J, Dugan, Jennifer L, Bruce, Charles J. , Attia, Zachi I. , DeSimone, Christopher V. , Dillon, John J., Somers, Virend K. , Scott, Christopher G. , Asirvatham, Samuel J

Mayo Clinic

Journal of the American Heart Association | January 25, 2016 | Volume: 5 | Issue: 1 | Pages: No page available

10.1161/jaha.115.002746 | PMID 26811164 Get It

Background Hyper‐ and hypokalemia are clinically silent, common in patients with renal or cardiac disease, and are life threatening. A noninvasive, unobtrusive, blood‐free method for tracking potassium would be an important clinical advance. Methods and Results Two groups of hemodialysis patients (development group, n=26; validation group, n=19) underwent high‐resolution digital ECG recordings and had 2 to 3 blood tests during dialysis. Using advanced signal processing, we developed a personalized regression model for each patient to noninvasively calculate potassium values during the second and third dialysis sessions using only the processed single‐channel ECG . In addition, by analyzing the entire development group's first‐visit data, we created a global model for all patients that was validated against subsequent sessions in the development group and in a separate validation group. This global model sought to predict potassium, based on the T wave characteristics, with no blood tests required. For the personalized model, we successfully calculated potassium values with an absolute error of 0.36±0.34 mmol/L (or 10% of the measured blood potassium). For the global model, potassium prediction was also accurate, with an absolute error of 0.44±0.47 mmol/L for the training group (or 11% of the measured blood potassium) and 0.5±0.42 for the validation set (or 12% of the measured blood potassium). Conclusions The signal‐processed ECG derived from a single lead can be used to calculate potassium values with clinically meaningful resolution using a strategy that requires no blood tests. This enables a cost‐effective, noninvasive, unobtrusive strategy for potassium assessment that can be used during remote monitoring.
Off-Ice Anaerobic Power Does Not Predict On-Ice Repeated Shift Performance in Hockey
Peterson, Ben , Fitzgerald, John S. , Dietz, Calvin C., Ziegler, Kevin S., Baker, Sarah E. , Snyder, Eric M., Peterson, Ben J, Baker, Sarah E

Mayo Clinic

Journal of Strength and Conditioning Research | January 24, 2016 | Volume: 30 | Issue: 9 | Pages: 2375-2381

10.1519/jsc.0000000000001341 | PMID 26808844 Get It

Abstract Peterson, BJ, Fitzgerald, JS, Dietz, CC, Ziegler, KS, Baker, SE, and Snyder, EM. Off-ice anaerobic power does not predict on-ice repeated shift performance in hockey. J Strength Cond Res 30(9): 2375–2381, 2016—Anaerobic power is a significant predictor of acceleration and top speed in team sport athletes. Historically, these findings have been applied to ice hockey although recent research has brought their validity for this sport into question. As ice hockey emphasizes the ability to repeatedly produce power, single bout anaerobic power tests should be examined to determine their ability to predict on-ice performance. We tested whether conventional off-ice anaerobic power tests could predict on-ice acceleration, top speed, and repeated shift performance. Forty-five hockey players, aged 18–24 years, completed anthropometric, off-ice, and on-ice tests. Anthropometric and off-ice testing included height, weight, body composition, vertical jump, and Wingate tests. On-ice testing consisted of acceleration, top speed, and repeated shift fatigue tests. Vertical jump (VJ) ( r = −0.42; r = −0.58), Wingate relative peak power (WRPP) ( r = −0.32; r = −0.43), and relative mean power (WRMP) ( r = −0.34; r = −0.48) were significantly correlated ( p ≤ 0.05) to on-ice acceleration and top speed, respectively. Conversely, none of the off-ice tests correlated with on-ice repeated shift performance, as measured by first gate, second gate, or total course fatigue; VJ ( r = 0.06; r = 0.13; r = 0.09), WRPP ( r = 0.06; r = 0.14; r = 0.10), or WRMP ( r = −0.10; r = −0.01; r = −0.01). Although conventional off-ice anaerobic power tests predict single bout on-ice acceleration and top speed, they neither predict the repeated shift ability of the player, nor are good markers for performance in ice hockey.
Application of Epstein‐Barr Virus Serology to the Diagnosis and Staging of North American Patients with Nasopharyngeal Carcinoma
Neel, H. Bryan, Pearson, Gary R., Weiland, Louis H., Taylor, William F., Goepfert, H, Pilch, Ben Z., Lanier, Anne P., Huang, Andrew T. , Hyams, Vincent J., Levine, Paul H., Henle, Gertrude, Henle, Werner, Goodman, Max Justin

Mayo Clinic

Otolaryngology–Head and Neck Surgery | November 25, 2015 | Volume: 91 | Issue: 3 | Pages: 255-262

10.1177/019459988309100310 | PMID 6308537 Get It

From 1978 to 1981, 151 patients with nasopharyngeal carcinoma (NPC) were enrolled in a prospective, collaborative study of North American patients, most of them white. Thirty‐seven had World Health Organization (WHO) type 1 tumors, and 114 had WHO types 2 and 3 tumors. The anti‐Epstein‐Barr virus (EBV) profile of elevated antibody titers directed against viral capsid antigen and early antigen was seen in 85% of the patients with WHO types 2 and 3 tumors but in only 16% of the patients with WHO type 1 tumors. Geometric mean titers tended to be higher in higher stages of the disease in several staging systems. Low antibody‐dependent cellular cytotoxicity at diagnosis appears to reflect a poorer prognosis, and the determination of antibody titers by this assay may prove to be useful for identifying persons in whom recurrent disease is likely to develop after conventional therapy. Anti‐EBV titers can aid in diagnosis and treatment planning in patients with NPC, particularly those with occult primary NPC.